NRXP
NRX Pharmaceuticals Inc
2.90$
+1.9%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -39,900.0% | -45,887.5% | – | – | -52,450.0% | -87,000.0% | – | -1,194.6% | -377.7% | -402.2% | -806.1% | -582.6% | |
| – | 12.5% | 12.5% | – | – | 25.0% | 25.0% | – | 17.8% | 10.2% | 15.4% | 15.7% | 14.2% | |
| – | -15,037.5% | 3,025.0% | – | – | 1,075.0% | 300.0% | – | 28.1% | 8.2% | 14.1% | 12.6% | 12.9% | |
| – | 30,275.0% | 28,587.5% | – | – | -2,150.0% | -2,150.0% | – | 234.3% | 138.1% | 31.0% | -312.9% | -35.0% | |
| – | 50.0% | 12.5% | – | – | 0.0% | 0.0% | – | 0.0% | 0.0% | 0.0% | 81.5% | 26.4% | |
| – | – | 12.5% | – | – | – | – | – | -1,058.3% | -25.3% | -19.9% | -62.1% | -109.2% | |
| – | – | – | – | – | 22,100.0% | 117,000.0% | – | -237.6% | 19.9% | 0.0% | 37.4% | 1.0% | |
| – | -13,950.0% | 4,937.5% | – | – | 47,375.0% | 189,625.0% | – | 4,019.0% | 465.4% | 320.6% | 2,682.3% | 1,392.4% | |
| – | -53,837.5% | -40,950.0% | – | – | -5,075.0% | 102,625.0% | – | 1,766.1% | 62.4% | -101.5% | 1,814.1% | 700.5% | |
| – | -39,850.0% | -45,887.5% | – | – | -52,450.0% | -87,000.0% | – | -1,194.6% | -377.7% | -402.2% | -887.6% | -609.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.